Table 5.

Analysis of long-term mortality after acute PE according to the cancer type

	31–90-day mortality*		91-day-1-year mortality*		1–5-year mortality*
	n/N (%, 95% CI)	P **	n/N (%, 95% CI)	P **	n/N (%, 95% CI)	P **
Overall	34/354 (9.6, 6.8–12.7)		43/316 (13.6, 10.1–17.4)		71/266 (26.7, 21.4–32.0)
No cancer	16/245 (6.5, 3.7–9.8)		15/227 (6.6, 3.5–10.1)		34/207 (16.4, 11.1–21.7)
Cancer
Lung	4/20 (20.0, 5.0–35.0)	0.052	8/16 (50.0, 25.0–75.0)	<0.001	6/7 (85.7, 57.1–100.0)	< 0.001
CNS	0/11 (0, -)	1.000	3/10 (30.0, 0–60.0)	0.032	4/7 (57.1, 28.6–85.7)	0.020
Gynecological	5/17 (29.4, 11.8–52.9)	0.007	3/11 (27.3, 0–54.5)	0.041	5/8 (62.5, 25.0–87.5)	0.006
Hematological	2/13 (15.4, 0–38.5)	0.227	1/11 (9.1, 0–27.3)	0.543	4/10 (40.0, 10.0–70.0)	0.076
Stomach	4/10 (40.0, 10.0–70.0)	0.004	4/6 (66.7, 33.3–100.0)	<0.001	2/2 (100.0, -)	0.029
Colorectal	1/10 (10.0, 0–30.0)	0.505	2/9 (22.2, 0–55.6)	0.130	6/7 (85.7, 57.1–100.0)	< 0.001
Breast	0/9 (0, -)	1.000	3/9 (33.3, 11.1–66.7)	0.024	4/6 (66.7, 33.3–100.0)	0.010
Pancreas	0/4 (0, -)	1.000	0/4 (0, -)	1.000	3/4 (75.0, 25.0–100.0)	0.018
Prostate	0/4 (0, -)	1.000	0/4 (0, -)	1.000	1/4 (25.0, 0–75.0)	0.519
Kidney	1/3 (33.3, 0–100)	0.193	1/2 (50.0, 0–100.0)	0.135	1/1 (100.0, -)	1.000
Other	1/8 (12.5, 0–37.5)	0.431	3/7 (42.9, 0–85.7)	0.011	2/3 (66.7, 0–100.0)	0.077

^*Five patients without follow-up data after 30 days, four patients without follow-up data after 90 days, and seven patients without follow-up data after one year were only included in mortality analysis of the periods with available follow-up data

^**Compared to patients without any type of cancer

n - number of deaths; N - number of patients with available follow-up information; CI - confidence interval; CNS - central nervous system; PE - pulmonary embolism